Skip to main content

Market Overview

Zoetis Investors May Need Patience To See Bull Thesis Play Out

Zoetis Investors May Need Patience To See Bull Thesis Play Out

After a more than 15-percent gain in Zoetis Inc (NYSE: ZTS) since the start of 2017, analysts at Deutsche Bank see little incremental upside in the near-term.

Gregg Gilbert downgraded Zoetis' stock from Buy to Hold with an unchanged $65 price target as it has handily outperformed the S&P index and most of the pharmaceutical space.

Zoetis should still be considered as a core long-term position, but investors could find a "more attractive" entry point for new money elsewhere, the analyst said. A $65 price target assumes mid-single digit revenue growth over the next few years along with operating margin expansion and higher earnings growth.

In the meantime, there's little reason for investors to view rival Eli Lilly and Co (NYSE: LLY)'s earnings report of being a concern, Gilbert added. Specifically, Eli Lilly's animal health division was lower in its recent quarter and highlighted by a 14 percent decline in food animal revenue.

However, Zoetis' portfolio isn't an apples-for-apples comparison to Eli Lilly's as the relationship between the two companies has "not been very consistent."

Finally, Zoetis is expected to at the very least meet consensus estimates in its second-quarter earnings report given its strong momentum along with a higher growth and margin profile versus its peers.

"We believe the stock better reflects the strong and durable revenue and earnings growth potential in the attractive Animal Health industry," the analyst emphasized.

Related Links:

Looking For A Better Entry Point, BMO Downgrades Zoetis Shares

Benzinga's Top Upgrades, Downgrades For July 26, 2017

Latest Ratings for ZTS

Mar 2021Raymond JamesUpgradesMarket PerformOutperform
Mar 2021B of A SecuritiesUpgradesNeutralBuy
Feb 2021Credit SuisseMaintainsOutperform

View More Analyst Ratings for ZTS
View the Latest Analyst Ratings


Related Articles (ZTS)

View Comments and Join the Discussion!

Posted-In: Animal Health Deutsche Bank Gregg GilbertAnalyst Color Upgrades Analyst Ratings Best of Benzinga

Latest Ratings

CLVSHC Wainwright & Co.Maintains12.0
PDDDaiwa CapitalInitiates Coverage On180.0
RYAMRBC CapitalDowngrades11.0
XOMDZ BankUpgrades67.0
BWFGKeefe, Bruyette & WoodsUpgrades35.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at